Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/missense-palb2-germline-variant-disrupts-nuclear-localization-of-palb2-L8P47gXYaV
References (32)
-
C. Schneider, W. Rasband, K. Eliceiri (2012)
NIH Image to ImageJ: 25 years of image analysisNature Methods, 9
-
Sue Richards, Nazneen Aziz, S. Bale, D. Bick, Soma Das, J. Gastier-Foster, W. Grody, M. Hegde, E. Lyon, E. Spector, K. Voelkerding, H. Rehm (2015)
Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular PathologyGenetics in medicine : official journal of the American College of Medical Genetics, 17
-
Amélie Rodrigue, Guillaume Margaillan, Thiago Gomes, Yan Coulombe, G. Montalban, Simone Carvalho, L. Milano, Mandy Ducy, Giuliana De-Gregoriis, G. Dellaire, Wilson Jr, A. Monteiro, Marcelo Carvalho, J. Simard, J. Masson (2019)
A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressorNucleic Acids Research, 47
-
Xin Yang, Goska Leslie, Alicja Doroszuk, S. Schneider, Jamie Allen, Brennan Decker, Brennan Decker, Brennan Decker, A. Dunning, J. Redman, J. Scarth, Inga Plaskocinska, C. Luccarini, M. Shah, K. Pooley, L. Dorling, Andrew Lee, M. Adank, J. Adlard, K. Aittomäki, I. Andrulis, P. Ang, J. Barwell, J. Bernstein, Kristie Bobolis, Å. Borg, C. Blomqvist, K. Claes, P. Concannon, A. Cuggia, A. Cuggia, Julie Culver, F. Damiola, A. Pauw, O. Díez, Jill Dolinsky, S. Domchek, C. Engel, D. Evans, F. Fostira, J. Garber, L. Golmard, E. Goode, S. Gruber, E. Hahnen, Christopher Hake, T. Heikkinen, J. Hurley, R. Janavicius, Z. Kleibl, P. Kleiblova, I. Konstantopoulou, A. Kvist, H. LaDuca, Ann Lee, Ann Lee, F. Lesueur, E. Maher, A. Mannermaa, S. Manoukian, R. McFarland, W. Mckinnon, A. Meindl, K. Metcalfe, N. Taib, J. Moilanen, K. Nathanson, S. Neuhausen, P. Ng, T. Nguyen-Dumont, T. Nguyen-Dumont, S. Nielsen, F. Obermair, K. Offit, O. Olopade, L. Ottini, Judith Penkert, K. Pylkäs, P. Radice, S. Ramus, S. Ramus, V. Rudaitis, L. Side, Rachel Silva-Smith, Valentina Silvestri, A. Skytte, T. Slavin, J. Soukupová, C. Tondini, A. Trainer, G. Unzeitig, L. Usha, Thomas Hansen, J. Whitworth, M. Wood, C. Yip, S. Yoon, A. Yussuf, G. Zogopoulos, G. Zogopoulos, D. Goldgar, J. Hopper, G. Chenevix-Trench, P. Pharoah, S. George, J. Balmaña, C. Houdayer, C. Houdayer, P. James, Z. El-Haffaf, H. Ehrencrona, M. Janatová, P. Peterlongo, H. Nevanlinna, R. Schmutzler, Soo-Hwang Teo, M. Robson, T. Pal, F. Couch, J. Weitzel, A. Elliott, M. Southey, M. Southey, R. Winqvist, D. Easton, William Foulkes, William Foulkes, A. Antoniou, M. Tischkowitz (2019)
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
Keiko Suzuki, P. Bose, Rebecca Leong-Quong, D. Fujita, K. Riabowol (2010)
REAP: A two minute cell fractionation methodBMC Research Notes, 3
-
C. Cybulski, W. Kluźniak, T. Huzarski, D. Wokołorczyk, A. Kashyap, A. Jakubowska, M. Szwiec, T. Byrski, T. Dębniak, B. Górski, V. Sopik, M. Akbari, P. Sun, J. Gronwald, S. Narod, J. Lubiński (2015)
Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis.The Lancet. Oncology, 16 6
-
A. Antoniou, S. Casadei, T. Heikkinen, D. Barrowdale, K. Pylkäs, Jonathan Roberts, Andrew Lee, D. Subramanian, K. Leeneer, F. Fostira, E. Tomiak, S. Neuhausen, Z. Teo, Sofia Khan, K. Aittomäki, J. Moilanen, C. Turnbull, S. Seal, A. Mannermaa, A. Kallioniemi, G. Lindeman, S. Buys, I. Andrulis, P. Radice, C. Tondini, S. Manoukian, A. Toland, P. Miron, J. Weitzel, S. Domchek, B. Poppe, K. Claes, D. Yannoukakos, P. Concannon, J. Bernstein, P. James, D. Easton, D. Goldgar, J. Hopper, N. Rahman, P. Peterlongo, H. Nevanlinna, M. King, F. Couch, M. Southey, R. Winqvist, W. Foulkes, M. Tischkowitz (2014)
Breast-cancer risk in families with mutations in PALB2.The New England journal of medicine, 371 6
-
A. Piffer, É. Luporsi, C. Mathelin (2018)
[PALB2, a major susceptibility gene for breast cancer].Gynecologie, obstetrique, fertilite & senologie, 46 10-11
-
Laura Caleca, Irene Catucci, G. Figlioli, L. Cecco, T. Pesaran, M. Ward, S. Volorio, A. Falanga, M. Marchetti, M. Iascone, C. Tondini, A. Zambelli, J. Azzollini, S. Manoukian, P. Radice, P. Peterlongo (2018)
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein InteractionFrontiers in Oncology, 8
-
R. Buisson, J. Masson (2012)
PALB2 self-interaction controls homologous recombinationNucleic Acids Research, 40
-
K. Kuchenbaecker, J. Hopper, D. Barnes, K. Phillips, T. Mooij, M. Roos-Blom, Sarah Jervis, F. Leeuwen, R. Milne, N. Andrieu, D. Goldgar, M. Terry, M. Rookus, D. Easton, A. Antoniou, L. McGuffog, D. Evans, D. Barrowdale, D. Frost, J. Adlard, K. Ong, L. Izatt, M. Tischkowitz, R. Eeles, R. Davidson, S. Hodgson, Steve Ellis, C. Noguès, C. Lasset, D. Stoppa-Lyonnet, J. Fricker, L. Faivre, P. Berthet, M. Hooning, L. Kolk, C. Kets, M. Adank, E. John, Wendy Chung, I. Andrulis, M. Southey, M. Daly, S. Buys, A. Osorio, C. Engel, K. Kast, R. Schmutzler, T. Caldés, A. Jakubowska, J. Simard, M. Friedlander, S. McLachlan, E. Macháčková, L. Foretova, Y. Tan, C. Singer, E. Oláh, A. Gerdes, B. Arver, H. Olsson (2017)
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 317
-
Mandy Ducy, Laura Sesma-Sanz, Laure Guitton-Sert, Anahita Lashgari, Yuandi Gao, Nadine Brahiti, Amélie Rodrigue, Guillaume Margaillan, Marie-christine Caron, J. Côté, J. Simard, J. Masson (2019)
The Tumor Suppressor PALB2: Inside Out.Trends in biochemical sciences, 44 3
-
Ronak Patel, Neethu Shah, Andrew Jackson, R. Ghosh, Piotr Pawliczek, Sameer Paithankar, Aaron Baker, Kevin Riehle, Hailin Chen, S. Milosavljevic, C. Bizon, Shawn Rynearson, T. Nelson, G. Jarvik, H. Rehm, S. Harrison, Danielle Azzariti, B. Powell, L. Babb, S. Plon, A. Milosavljevic (2017)
ClinGen Pathogenicity Calculator: a configurable system for assessing pathogenicity of genetic variantsGenome Medicine, 9
-
K. Karczewski, L. Francioli, G. Tiao, Beryl Cummings, Jessica Alföldi, Qingbo Wang, Ryan Collins, Kristen Laricchia, A. Ganna, Daniel Birnbaum, L. Gauthier, H. Brand, M. Solomonson, N. Watts, Daniel Rhodes, M. Singer-Berk, E. Seaby, J. Kosmicki, R. Walters, K. Tashman, Y. Farjoun, E. Banks, T. Poterba, Arcturus Wang, C. Seed, N. Whiffin, Jessica Chong, K. Samocha, E. Pierce-Hoffman, Z. Zappala, A. O’Donnell-Luria, E. Minikel, B. Weisburd, M. Lek, J. Ware, C. Vittal, Irina Armean, Louis Bergelson, K. Cibulskis, K. Connolly, Miguel Covarrubias, S. Donnelly, S. Ferriera, S. Gabriel, Jeff Gentry, N. Gupta, Thibault Jeandet, D. Kaplan, Christopher Llanwarne, Ruchi Munshi, Sam Novod, Nikelle Petrillo, David Roazen, Valentín Ruano-Rubio, A. Saltzman, M. Schleicher, José Soto, Kathleen Tibbetts, C. Tolonen, Gordon Wade, M. Talkowski, B. Neale, M. Daly, D. MacArthur (2019)
Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genesbioRxiv
-
D. MacArthur, D. MacArthur, T. Manolio, D. Dimmock, H. Rehm, J. Shendure, G. Abecasis, D. Adams, R. Altman, S. Antonarakis, Euan Ashley, J. Barrett, L. Biesecker, D. Conrad, G. Cooper, Nancy Cox, M. Daly, M. Daly, M. Gerstein, David Goldstein, J. Hirschhorn, J. Hirschhorn, S. Leal, L. Pennacchio, L. Pennacchio, J. Stamatoyannopoulos, S. Sunyaev, David Valle, B. Voight, W. Winckler, W. Winckler, C. Gunter (2014)
Guidelines for investigating causality of sequence variants in human diseaseNature, 508
-
Jung-young Park, T. Singh, N. Nassar, Fan Zhang, M. Freund, H. Hanenberg, A. Meetei, P. Andreassen (2013)
BREAST CANCER-ASSOCIATED MISSENSE MUTANTS OF THE PALB2 WD40 DOMAIN, WHICH DIRECTLY BINDS RAD51C, RAD51 AND BRCA2, DISRUPT DNA REPAIROncogene, 33
-
M. Tischkowitz, B. Xia, N. Sabbaghian, J. Reis-Filho, N. Hamel, Guilan Li, E. Beers, Lili Li, T. Khalil, Louise Quenneville, A. Omeroglu, A. Poll, P. Lepage, N. Wong, P. Nederlof, A. Ashworth, P. Tonin, S. Narod, D. Livingston, W. Foulkes (2007)
Analysis of PALB2/FANCN-associated breast cancer familiesProceedings of the National Academy of Sciences, 104
-
Prateek Kumar, S. Henikoff, P. Ng (2009)
Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithmNature Protocols, 4
-
H. Erkko, B. Xia, J. Nikkilä, J. Schleutker, K. Syrjäkoski, A. Mannermaa, A. Kallioniemi, K. Pylkäs, S. Karppinen, K. Rapakko, A. Miron, Qing Sheng, Guilan Li, Henna Mattila, D. Bell, D. Haber, Mervi Grip, M. Reiman, A. Jukkola-Vuorinen, A. Mustonen, J. Kere, L. Aaltonen, V. Kosma, V. Kataja, Y. Soini, R. Drapkin, D. Livingston, R. Winqvist (2007)
A recurrent mutation in PALB2 in Finnish cancer familiesNature, 446
-
H. Hanenberg, P. Andreassen (2018)
PALB2 (partner and localizer of BRCA2)Atlas of genetics and cytogenetics in oncology and haematology, 22
-
I. Adzhubei, S. Schmidt, L. Peshkin, V. Ramensky, A. Gerasimova, P. Bork, A. Kondrashov, S. Sunyaev (2010)
A method and server for predicting damaging missense mutationsNature methods, 7
-
M. Toh, Chiang Jian, S. Chong, S. Chan, Nur Ishak, Eliza Courtney, W. Lee, Syed Al, John Allen, K. Lim, S. Davila, P. Tan, W. Lim, I. Tan, J. Ngeow (2018)
Germline Pathogenic Variants in Homologous Recombination and DNA Repair Genes in an Asian Cohort of Young-Onset Colorectal CancerJNCI Cancer Spectrum, 2
-
(2018)
PALB 2 , gène majeur de susceptibilité au cancer du sein -
A. Desmond, A. Kurian, M. Gabree, M. Mills, Michael Anderson, Yuya Kobayashi, N. Horick, Shan Yang, K. Shannon, N. Tung, J. Ford, S. Lincoln, L. Ellisen (2015)
Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.JAMA oncology, 1 7
-
Jean-Yves Bleuyard, R. Buisson, J. Masson, F. Esashi (2012)
ChAM, a novel motif that mediates PALB2 intrinsic chromatin binding and facilitates DNA repairEMBO reports, 13
-
D. Tchernitchko, M. Goossens, H. Wajcman (2004)
In silico prediction of the deleterious effect of a mutation: proceed with caution in clinical genetics.Clinical chemistry, 50 11
-
Joris Pauty, Anthony Couturier, Amélie Rodrigue, Marie-christine Caron, Yan Coulombe, G. Dellaire, J. Masson (2017)
Cancer-causing mutations in the tumor suppressor PALB2 reveal a novel cancer mechanism using a hidden nuclear export signal in the WD40 repeat motifNucleic Acids Research, 45
-
T. Heikkinen, Hanni Kärkkäinen, Kirsimari Aaltonen, R. Milne, P. Heikkilä, K. Aittomäki, C. Blomqvist, H. Nevanlinna (2009)
The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor PhenotypeClinical Cancer Research, 15
-
S. Phuah, S. Lee, P. Kang, I. Kang, S. Yoon, M. Thong, M. Hartman, J. Sng, C. Yip, N. Taib, S. Teo (2013)
Prevalence of PALB2 Mutations in Breast Cancer Patients in Multi-Ethnic Asian Population in Malaysia and SingaporePLoS ONE, 8
-
M. Wong-Brown, K. Avery-Kiejda, N. Bowden, R. Scott (2014)
Low prevalence of germline PALB2 mutations in Australian triple‐negative breast cancerInternational Journal of Cancer, 134
-
S. Tavtigian, Amie Deffenbaugh, L. Yin, T. Judkins, T. Scholl, P. Samollow, D. Silva, A. Zharkikh, Alun Thomas (2005)
Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutralJournal of Medical Genetics, 43
-
B. Xia, J. Dorsman, N. Ameziane, Y. Vries, M. Rooimans, Qing Sheng, G. Pals, A. Errami, E. Gluckman, Julián Llera, Weidong Wang, D. Livingston, H. Joenje, J. Winter (2007)
Fanconi anemia is associated with a defect in the BRCA2 partner PALB2Nature Genetics, 39
- Publisher
- Springer Journals
- Copyright
- Copyright © Springer Nature B.V. 2020
- ISSN
- 1389-9600
- eISSN
- 1573-7292
- DOI
- 10.1007/s10689-020-00163-8
- Publisher site
- See Article on Publisher Site
Abstract
The PALB2 protein is essential to RAD51-mediated homologous recombination (HR) repair. Germline monoallelic PALB2 pathogenic variants confer significant risks for breast cancer. However, the majority of PALB2 variants remain classified as variants of unknown significance (VUS). We aim to functionally and mechanistically evaluate three novel PALB2 VUS. Patient-derived lymphoblastoid cell lines containing the VUS were analyzed for nuclear localization and foci formation of RAD51 as a measure of HR efficiency. To understand the mechanism underlying the HR deficiency, PALB2 nuclear localization was assessed using immunofluorescence studies. Among these VUS, c.3251C>T (p.Ser1084Leu) occurred in a patient with metastatic breast cancer while c.1054G>C (p.Glu352Gln) and c.1057A>G (p.Lys353Glu) were seen in patients with squamous cell carcinoma of skin and renal cell carcinoma respectively. Variant c.3251C>T was located within the WD40 domain which normally masked the nuclear export signal sequence responsible for nuclear delocalization of PALB2. Correspondingly, c.3251C>T displayed aberrant cytoplasmic localization of PALB2 which led to an impaired RAD51 nuclear localization and foci formation. On the other hand, both c.1054G>C and c.1057A>G showed intact HR functions and nuclear localization of PALB2, consistent with their locations within domains of no known function. Additionally, the prevalence of c.1054G>C was similar among healthy controls and patients with breast cancer (as seen in other studies), suggestive of its non-pathogenicity. In conclusion, our studies provided the functional evidence showing the deleterious effect of c.3251C>T, and non-deleterious effects of c.1054G>C and c.1057A>G. Using the ClinGen Pathogenicity calculator, c.3251C>T remains a VUS while c.1054G>C and c.1057A>G may be classified as likely benign variants.
Journal
Familial Cancer – Springer Journals
Published: Apr 11, 2020